H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy

SelfRugger · 2026-02-27T11:10:32+00:00

H.C. Wainwright raised its target price for Protagonist Therapeutics, Inc. (PTGX) to $117, citing its successful drug development. The company has promising late-stage assets and strong partnerships, though some AI stocks may offer better growth potential.

SelfRugger

2026-02-27 11:10:32

Abstract generation in progress

H.C. Wainwright Raises Protagonist Therapeutics, Inc. (PTGX) Target to $117, Reiterates Buy

Sajjl Nooranne

Thu, February 12, 2026 at 5:13 AM GMT+9 1 min read

In this article:

PTGX

-0.51%

JNJ

+0.99%

TAK

+1.05%

We recently published an article titled 10 Best Long Term Healthcare Stocks to Buy.

On January 30, H.C. Wainwright raised its price target on Protagonist Therapeutics, Inc. (NASDAQ:PTGX) to $117 from $80 and reiterated a Buy rating. The firm cited the company’s track record in drug development and assigned probability-of-success assumptions across multiple programs, including PN-8047, its IL-4R antagonist, and obesity assets.

In early February, a company director sold 20,000 shares in a transaction valued at approximately $1.7 million, an event monitored by investors alongside ongoing pipeline developments. Protagonist Therapeutics, Inc. (NASDAQ:PTGX) recently reported having two potential late-stage assets, Icotrokinra and Rusfertide, with NDAs submitted in 2025 for plaque psoriasis and polycythemia vera, respectively. The company also expects multiple Phase 2 and Phase 3 readouts across immunology, hematology, and obesity indications. Existing partnerships with Johnson & Johnson and Takeda include milestone and royalty structures that support non-dilutive funding.

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) was founded on August 22, 2006, and is headquartered in Newark, California. The company develops peptide-based therapies targeting rare diseases, hematology, and immunology.

While we acknowledge the potential of PTGX as a long term investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

**READ NEXT: 8 Up and Coming Streaming Companies and Services and **9 High Growth Canadian Stocks to Buy

Disclosure: None.

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.